• 2. Anti-Na V 1.5 (SCN5A) (1978-2016) Antibody, preincubated with Nav1.5/SCN5A (1978-2016) Blocking Peptide (#BLP-SC013). (alomone.com)
  • To evaluate the Swarm screening system, we optimized a series of heterologous optogenetic spiking HEK293 cell assays for several voltage-gated sodium channel subtypes including Nav1.2, Nav1.5, and Nav1.7. (frontiersin.org)
  • The syndrome is caused by changes in the structure and function of certain cardiac ion channels and reduced expression of Connexin 43 (Cx43) in the Right Ventricle (RV), predominantly in the Right Ventricular Outflow Tract (VSVD), causing electromechanical abnormalities. (bvsalud.org)
  • Optogenetic assays provide a flexible, scalable, and information rich approach to probe compound effects for ion channel drug targets in both heterologous expression systems and associated disease relevant cell types. (frontiersin.org)
  • The diagnosis is based on the presence of spontaneous or medicated ST elevation, characterized by boost of the J point and the ST segment ≥ 2 mm, of superior convexity "hollow type" (subtype 1A) or descending rectilinear model (subtype 1B). (bvsalud.org)
  • While once a first-line treatment for hypertension , they do not perform as well as other drugs, particularly in the elderly, and evidence is increasing that the most frequently used beta blockers at usual doses carry an unacceptable risk of provoking type 2 diabetes. (epiphanyasd.com)
  • Type 2 Diabetes Mellitus, also known as insulin resistance, is related to diabetes mellitus and maturity-onset diabetes of the young, type 8, with exocrine dysfunction, and has symptoms including angina pectoris, tremor and equilibration disorder. (silexon.tech)
  • An important gene associated with Type 2 Diabetes Mellitus is IRS1 (Insulin Receptor Substrate 1), and among its related pathways/superpathways are Nervous system development and Angiopoietin-like protein 8 regulatory pathway. (silexon.tech)
  • Note: If you'd like to get a target analysis report for Diabetes Type 2 , or if you are interested to learn how our AI-powered BDE-Chem can design therapeutic molecules to interact with the target(s) above against the disease of Diabetes Type 2 at a cost 90% lower than traditional approaches, please feel free to contact us at [email protected] . (silexon.tech)